The Pharma Data

JULY 29, 2021

Lilly plans to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year. 3 The current annual societal and economic cost of dementia is estimated at $1 trillion, an amount that is expected to double by 2030 unless we find a way to slow the disease.

Disease 52

Disease Treatment Pharmacokinetics Trials 52

The Pharma Data

MAY 4, 2021

.” The arrangement is part of Lilly ‘s philanthropic efforts and supports Lilly 30×30, the company’s goal to improve access to quality health care for 30 million people living in settings with limited resources, each year, by 2030. It is approved in the U.S. We call this global effort Lilly 30×30.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

AUGUST 5, 2021

Earnings were also diminished by a negative product mix, currency effects of 111 million euros, and the later receipt of license revenues. Through this amendment, Bayer has emphasized its commitment to achieving climate neutrality by 2030 and its holistic sustainability strategy. Pharmaceuticals raises sales and earnings.

Production 52

Production Pharmaceuticals Science Therapies 52

FDA Law Blog: Biosimilars

DECEMBER 11, 2023

FDA’s assumption that 50% of the tests will be exempt is particularly baffling because the laboratories are ones licensed to perform high complexity tests. In seeking to justify regulation of LDTs, FDA emphasizes that many of these tests are novel. [6] By their very nature, these tests are less likely to be exempt from FDA review.

FDA 69

FDA Laboratories Regulations Production 69

The Pharma Data

JANUARY 9, 2021

Pipeline progress is expected across the vaccines, therapeutics, and devices portfolios, anticipating at least one Phase 3 launch and one Biologics License Application (BLA)/Emergency Use Authorization (EUA) filing. In working together, we envision protecting or enhancing 1 billion lives by 2030. FOOTNOTES. (1)

Government 40

Government Vaccine Production Licensing 40

The Pharma Data

NOVEMBER 5, 2020

The FDA accepted for priority review, with a target action date of February 28, 2021 , the supplemental Biologics License Application (sBLA) for Libtayo ® (cemiplimab) as monotherapy to treat patients with first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) with ?50% Oncology Program. 50% PD-L1 expression.

Production 40

Production FDA Trials FDA Approval 40

The Pharma Data

APRIL 27, 2021

District Court for the District of Delaware asserting two method of use patents (US 10,583,110 and US 10, 716,777), both of which expire in October 2030. On January 12, 2021 Sanofi entered into a global licensing agreement with Biond Biologics for BND-22, a novel immune checkpoint inhibitor targeting the ILT2 receptor. Collaborations.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

MAY 18, 2021

This business developed positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. The program aims to reach 50 million people annually in these regions by 2030 through direct action and in partnership with major NGOs.

Science 40

Science Pharmaceuticals Production Marketing 40

The Pharma Data

FEBRUARY 8, 2021

District Court for the District of Delaware asserting two method of use patents (US 10,583,110 and US 10, 716,777), both of which lasts until October 2030. In Europe, where the product is commercially available in several countries and has a temporary license to be sold in France, sales were €12 million. glucosidase deficiency).

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

FEBRUARY 4, 2021

District Court for the District of Delaware asserting two method of use patents (US 10,583,110 and US 10, 716,777), both of which lasts until October 2030. In Europe, where the product is commercially available in several countries and has a temporary license to be sold in France, sales were €12 million. glucosidase deficiency).

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

JULY 11, 2021

These data represent an important public health milestone in our efforts to advanc e protection against meningococcal meningitis and in support of the World Health Organization ’s ambition to defeat this disease by 2030.”. Su-Peing Ng, Global Medical Head, Sanofi Pasteur. About the Phase 3 study 4 , 5.

Immune Response 52

Immune Response Disease Vaccine Licensing 52

The Pharma Data

NOVEMBER 22, 2020

Alzprotect co-owns or has an exclusive worldwide license from the French National Institute of Health and Medical research (Inserm) and the University of Lille (France) on a total of 58 patents related to Ezeprogind in 39 countries. The average life expectancy of PSP patients ranges from 5 to 7 years.

Drugs 40

Drugs Disease Clinical Trials Licensing 40

Agency IQ

MAY 28, 2024

CE mark in addition to its own UKCA mark, with a plan to continue doing so through 2028 or 2030, depending on the legislation to which the CE mark applies. Additionally, companion diagnostics and combination products that contain medicinal substances that haven’t yet been licensed in the U.K. Presently, the U.K. recognizes the E.U.

International 40

International Regulations Licensing Licensing 40

Agency IQ

JUNE 16, 2023

Final Rule Stage Clean Water Act Section 401: Water Quality Certification 2040-AG12 August 2023 Clean Water Act (CWA) section 401 provides States and Tribes with a powerful tool to protect the quality of their waters from adverse impacts resulting from federally licensed or permitted projects.

Regulations 40

Regulations Compliance Production Science 40